We are live on
!
Find out more
CG
Carlyle Group Portfolio holdings
AUM
$10B
1-Year Est. Return
10.61%
This Fund
S&P 500
This Quarter
Est. Return
-4.39%
1 Year Est. Return
-10.61%
3 Year Est. Return
-7.98%
5 Year Est. Return
-20.78%
10 Year Est. Return
-1.56%
AUM
$10B
AUM Growth
-$618M
(-5.8%)
Cap. Flow
-$14.8M
Cap. Flow
% of AUM
-0.15%
Top 10 Holdings %
Top 10 Hldgs %
99.94%
Holding
23
New
3
Increased
2
Reduced
2
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SunPower Inc
SPWR
|
+$1.87M |
| 2 |
Riley Exploration Permian
REPX
|
+$574K |
| 3 |
NBIS
Nebius Group N.V.
NBIS
|
+$366K |
| 4 |
Ramaco Resources Class A
METC
|
+$317K |
| 5 |
Robinhood
HOOD
|
+$114K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Q32 Bio
QTTB
|
+$8.71M |
| 2 |
CubeSmart
CUBE
|
+$8.08M |
| 3 |
HTFL
Heartflow Inc
HTFL
|
+$497K |
| 4 |
Spyre Therapeutics
SYRE
|
+$485K |
| 5 |
Exicure
XCUR
|
+$240K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.22% |
| 2 | Industrials | 25.31% |
| 3 | Real Estate | 0.2% |
| 4 | Technology | 0.18% |
| 5 | Communication Services | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDLN
1
Medline Inc
MDLN
$32.1B
| $7.38B | 73.78% |
187,083,713
| – | – |
|
|
SARO
2
StandardAero Inc
SARO
$8.15B
| $2.53B | 25.3% |
84,587,035
| – | – |
|
3
Phathom Pharmaceuticals
PHAT
$732M
| $37.9M | 0.38% |
3,496,808
| – | – |
|
4
Invitation Homes
INVH
$16.9B
| $20M | 0.2% |
662,900
-1,200
| -0.2% | -$33.9K |
|
|
PONY
5
Pony AI Inc
PONY
$3.13B
| $16.4M | 0.16% |
2,362,447
| – | – |
|
6
Getty Images
GETY
$97M
| $5.36M | 0.05% |
6,234,252
| – | – |
|
|
SPRB
7
Spruce Biosciences
SPRB
$166M
| $2.09M | 0.02% |
38,620
| – | – |
|
|
8
SunPower Inc
SPWR
$83.9M
| $1.61M | 0.02% |
2,343,750
+1,910,592
| +441% | +$1.87M |
|
9
Adicet Bio
ACET
$88.3M
| $1.59M | 0.02% |
184,295
| – | – |
|
10
Forward Air
FWRD
$551M
| $1.45M | 0.01% |
107,214
| – | – |
|
|
OKUR
11
OnKure Therapeutics
OKUR
$144M
| $1.23M | 0.01% |
269,895
| – | – |
|
12
Krispy Kreme
DNUT
$579M
| $1.2M | 0.01% |
340,748
| – | – |
|
|
13
Q32 Bio
QTTB
$381M
| $769K | 0.01% |
60,363
-1,042,378
| -95% | -$8.71M |
|
|
14
Riley Exploration Permian
REPX
$932M
| $530K | 0.01% |
+16,092
| New | +$574K |
|
|
NBIS
15
Nebius Group N.V.
NBIS
$57.3B
| $510K | 0.01% |
+1,846
| New | +$366K |
|
|
16
Robinhood
HOOD
$112B
| $475K | ﹤0.01% |
4,733
+1,357
| +40% | +$114K |
|
17
Jasper Therapeutics
JSPR
$22.8M
| $449K | ﹤0.01% |
1,066,189
| – | – |
|
18
N-able
NABL
$754M
| $344K | ﹤0.01% |
93,732
| – | – |
|
|
19
Ramaco Resources Class A
METC
$783M
| $288K | ﹤0.01% |
+21,743
| New | +$317K |
|
|
20
CubeSmart
CUBE
$8.95B
| – | – |
-220,500
| Closed | -$8.08M |
|
|
21
Spyre Therapeutics
SYRE
$7.69B
| – | – |
-9,620
| Closed | -$485K |
|
|
22
Exicure
XCUR
$8.05M
| – | – |
-56,328
| Closed | -$240K |
|
|
HTFL
23
Heartflow Inc
HTFL
$4.32B
| – | – |
-20,438
| Closed | -$497K |
|
Similar funds
LA
NW
AC
BCM
OIAM
AI
AI
SWP
Carlyle Group's Q2 2026 Portfolio in Review
As of Q2 2026, Carlyle Group held 23 positions worth $10B, down 5.8% from $10.6B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Carlyle Group's Q2 2026 filing shows 3 new, 2 increased, 2 reduced and 4 closed positions. Its largest new stake was Riley Exploration Permian: 16,092 shares worth $530K. The largest sale was Q32 Bio, an estimated $8.71M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 79% a quarter earlier, followed by Industrials and Real Estate.
- Carlyle Group's largest Q2 2026 buy was Riley Exploration Permian: 16,092 shares worth $530K.
- Carlyle Group added most to SunPower Inc in Q2 2026, an estimated $1.87M increase.
- Carlyle Group's biggest Q2 2026 reduction was Q32 Bio, cutting an estimated $8.71M.
- Carlyle Group fully exited CubeSmart in Q2 2026, selling an estimated $8.08M.
- Carlyle Group's ten largest holdings make up 100% of its $10B portfolio in Q2 2026.
- Carlyle Group opened 3 new positions and closed 4 in Q2 2026.
- Carlyle Group's portfolio value fell 5.8% quarter-over-quarter to $10B.
Based on Carlyle Group's 13F filing for Q2 2026, filed 7 Aug 2026.